NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, announced it will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, in Fort Lauderdale, Florida. The presentation comes as the company advances NV-387, a broad-spectrum antiviral, in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. The news matters because it signals progress in developing a single drug that could treat multiple high-consequence viral infections, a departure from traditional one-virus-one-drug approaches.
NV-387 is also being planned for clinical trials in measles, for which it has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration, as well as for viral acute respiratory infections. The company's pipeline includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS. For investors, the conference presentation provides an opportunity to learn more about NanoViricides' platform and its potential to address unmet medical needs. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
NanoViricides is creating special purpose nanomaterials for antiviral therapy based on its novel nanoviricide class of drug candidates. The technology is derived from intellectual property and know-how of TheraCour Pharma, Inc., with which NanoViricides has a Memorandum of Understanding for the development of drugs for all antiviral infections, excluding cancer and similar diseases. The company holds broad, exclusive, sub-licensable field licenses from TheraCour for several licensed fields. Its business model centers on licensing technology for specific application verticals of specific viruses, established at its foundation in 2005.
The lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Another advanced candidate, NV-HHV-1, targets Shingles. The company is also developing drugs against oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology is based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
For more information about NanoViricides, visit www.nanoviricides.com. To view the full press release, visit https://ibn.fm/vQCM4. The company's progress is closely watched by investors and public health experts alike, as successful development of a broad-spectrum antiviral could transform responses to outbreaks and endemic viral diseases. However, as with any drug development, the path is lengthy and requires substantial capital, and there can be no assurance that any candidates will show sufficient effectiveness and safety for human clinical development.
The announcement was distributed via InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers, see https://www.InvestorWire.com/Disclaimer.
